ECF506

ECF506 (NXP900) is a highly potent and orally active YES1/SRC kinase inhibitor with an IC50 of 0.47 nM. eCF506 locks its target into its native “closed” conformation, thereby inhibiting both kinase activity and complex formation with protein partners. eCF506 can be used for the study of esophageal squamous cancer and breast cancer[1].

Product Specifications

CAS Number

[1914078-41-3]

Product Name Alternative

NXP900

UNSPSC

12352005

Hazard Statement

H315, H317, H318, H334, H335, H341, H361, H370, H413

Target

Src

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/eCF506.html

Concentration

10mM

Purity

99.77

Solubility

DMSO : 62.5 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)

Smiles

NC1=C2C(C3=CC(OC)=C(NC(OC(C)(C)C)=O)C=C3)=NN(CCN4CCC(N(C)C)CC4)C2=NC=N1

Molecular Formula

C26H38N8O3

Molecular Weight

510.63

Precautions

H315, H317, H318, H334, H335, H341, H361, H370, H413

References & Citations

[1]Fraser C, et al. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. J Med Chem. 2016 May 26;59 (10) :4697-710.|[2]Authors: Sweta Dash, et al. Preclinical efficacy of NXP900, a YES1/SRC kinase inhibitor in esophageal squamous cancer models. Journal of Clinical Oncology. Volume 41, Number 16_suppl.